This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Comment: Sanofi-Maze block from US FTC lends legitimacy to early-stage pharmaceutical challenges, raises issues for future deals

By Serafina Smith and Flavia Fortes ( December 22, 2023, 16:03 GMT | Comment) -- The US Federal Trade Commission’s move to block Sanofi’s proposed licensing agreement with Maze Therapeutics last week — the agency’s first challenge of an unconsummated merger involving a Phase 1 pipeline drug — has advanced the FTC’s goals for stronger enforcement of early-stage pharmaceutical deals. While the companies abandoned the transaction and the courts won’t weigh in on whether early-stage pipeline drugs should be considered in the competitive analysis, the challenge could still have ramifications for dealmakers and biopharmaceutical companies.The US Federal Trade Commission’s move to block Sanofi’s proposed licensing agreement with Maze Therapeutics last week — the agency’s first challenge of an unconsummated merger involving a Phase 1 pipeline drug — has advanced the FTC’s goals for stronger enforcement of early-stage pharmaceutical deals....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login